SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

PRINCETON, N.J., Nov. 13, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced the presentation ...

BASH is a Unix shell and command language which can run Shell Script files. You do not need to install Ubuntu or any other Linux Distros unless your scripts need the ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for ...

Late-breaking oral presentation of interim safety and efficacy data from the phase 1 study of SBT-77-7101, including a favorable early safety profile, with preliminary clinical and mechanistic ...

BOSTON, October 02, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming ...

The real estate listing presentation is one of the most critical tools in your arsenal for demonstrating your knowledge, expertise, experience and authenticity to seller leads. A well-done listing ...

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...

Please provide your email address to receive an email when new articles are posted on . Mid- to late-career medical oncologists from NCI-designated cancer centers delivered a high percentage of oral ...

Prior to the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, I put together a preview article focused on the biotech-related stories coming out of the various oral presentations at ...

“Over the last year, our progress on two preclinical gene therapy programs as well as our novel AAV capsid discovery platform has been remarkable,” said P. Peter Ghoroghchian, MD, PhD, CEO of Latus.

Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...